Jenburkt Pharmaceuticals has promoted Prem Ashish Bhuta to the position of Associate Vice President (AVP) – Strategic Initiatives. The elevation, approved by the Board of Directors via circulation on September 4, 2026, takes effect immediately.

Bhuta, who joined the company on July 13, 2021, moves up from his previous role as Management Associate. The appointment follows recommendations from the Nomination and Remuneration Committee and received prior approval from the Audit Committee. This move aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Profile and Experience

Bhuta, aged 26, holds a Master of Science in Integrated Marketing from New York University and a Bachelor of Commerce (Honours) from Narsee Monjee Institute of Management Studies, Mumbai. He brings over five years of cross-functional experience across finance, sales, marketing operations, and business analytics within the pharmaceutical sector.

During his tenure at Jenburkt, Bhuta progressed through roles including Management Trainee and Officer – Finance. His responsibilities have spanned new product development, e-commerce, sales tracking, inventory management, and exposure to manufacturing processes.

Strategic Contributions

Bhuta was part of the core team that built ZIXA Strong, an OTC topical pain relief brand under the company’s wellness division. He also contributed to broader technology modernization efforts, including:

• Deployment of artwork management software
• Upgrade of the Laboratory Information Management System (LIMS)
• Rollout of a real-time sales tracking application used by a field force of over 700 employees

Prior to joining Jenburkt, Bhuta undertook strategic research projects with organizations such as Samsung Electronics America and Coca-Cola Southwest Beverages during his academic tenure in the United States.

Related Party Disclosure

The filing discloses that Bhuta is related to Ashish U. Bhuta, the Promoter and Chairman & Managing Director of Jenburkt Pharmaceuticals. The details of the appointment were filed with BSE Ltd. under Ref. No.: JPL/CS/2342/2026.

Jenburkt Pharmaceuticals reported a 24.45% year-on-year decline in standalone net profit after tax (PAT) for Q1FY27, dropping to ₹5.89 crore (₹588.56 lakhs). The contraction in profitability was driven by rising operational expenses, particularly in employee benefits, while revenue from operations remained virtually flat at ₹35.51 crore. The results were approved by the Board of Directors on August 6, 2026, and published in newspapers on August 7, 2026.

The Board of Directors approved the unaudited financial results following a review by the Audit Committee. The results were prepared in accordance with Ind AS 34 and reviewed by statutory auditors D.R. Mehta & Associates under Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The limited review report confirmed no material misstatements. Ashish U. Bhuta, Chairman & Managing Director, signed off on the results, which were subsequently published in The Free Press Journal (English) and Navshakti (Marathi) on August 7, 2026.

Financial Performance

Revenue from operations stood at ₹3,551.20 lakhs, marginally down from ₹3,552.68 lakhs in Q1FY26. Total income reached ₹3,702.52 lakhs, including other income of ₹151.32 lakhs. This represents a significant drop in other income from ₹434.83 lakhs in Q4FY26. Profit before tax fell to ₹676.91 lakhs from ₹1,018.20 lakhs in the same period last year. Basic and diluted earnings per share (EPS) decreased to ₹13.34 from ₹17.66 in Q1FY26.

What the Numbers Show

The primary driver behind the profit decline was a surge in employee benefit expenses, which rose to ₹1,302.52 lakhs in Q1FY27 from ₹1,172.08 lakhs in Q1FY26. This increase outpaced the negligible growth in revenue, squeezing operating margins. Additionally, other expenses climbed to ₹1,013.81 lakhs from ₹833.11 lakhs year-on-year. While cost of materials consumed decreased slightly to ₹231.59 lakhs, the overall expense burden increased relative to income generation. The absence of exceptional items in Q1FY27 contrasts with Q4FY26, where a one-time gain of ₹395.11 lakhs related to Labour Code impacts had boosted profits.